The genesis of Accendo's segmented flow development began with the Conjure in 2003 as a collaboration between Accendo Corporation, Pfizer and Wyeth Pharmaceuticals. The primary objective was to exploit the power of flow reactors to broaden chemistry space and increase laboratory efficiencies in medicinal chemistry and process research. The concept was to create a single flow system that could has the flexibility of scale (milligram to grams) with broad chemistry utility:

• Reaction Optimization
• Library Synthesis
• Scaffold Scale Up
• Route Scouting
• Screening
• Intermediate Scale Up

Accendo Corporation´s contribution to the collaboration was the technology development, manufacturing and support. The collaborators provided the chemistry and laboratory perspective — preparation of reaction mixtures, temperature range, integration of design of experimentation, online LC/MS analysis, user programming interface and most importantly validation.

Multiple first generation Conjures were installed at each collaborators facilities, medicinal chemistry and process research. Throughout a two year period, the collaborators provided concepts for hardware and software enhancements. Accendo routinely provided new hardware and software support until the team agreed that the Conjure was ready for broad commercialization to the drug discovery industry.

To learn how the collaborators validated the Conjure hardware and software, click on the link for The Validation.